Research Primates' Diarrhea Outbreak Provides Data for Shigella Vaccine Development

Outbreak Yields Unexpected Data

A two-year diarrhea outbreak affecting more than 150 non-human primates at a research center provided scientists with valuable immunological data. This unexpected event allowed researchers to study natural Shigella infections in detail, which is crucial for understanding immune responses.

Advancing Shigella Vaccine Design

In a study published in Science Translational Medicine, scientists analyzed the immunological data from the primate infections. They identified specific bacterial components that the immune system effectively targets and linked these target molecules to particular germ-fighting immune responses. The research also pinpointed precise sites on these molecules where potent antibodies attach.

Addressing a Global Health Challenge

Shigella causes over 200 million infections and 200,000 deaths annually, primarily among children. While survivors often develop some immunity, it is typically narrow, effective against only a limited range of Shigella types. Additionally, Shigella strains are increasingly resistant to antibiotics, highlighting the urgent need for a comprehensive vaccine.

Toward a Rational Vaccine Candidate

The study's findings revealed previously unknown aspects of the anti-Shigella antibody response in naturally infected primates. This detailed molecular and structural data is essential for the rational design of Shigella vaccine candidates that can combat multiple species and serotypes of the bacteria, a goal that has eluded previous development efforts.